Baxter and Olayan Group reach milestone in expanding renal therapy services in Saudi

Baxter (NYSE:BAX), a leading global medical products company and a global innovator in renal care, today signed an agreement with the Olayan Group, a private multinational enterprise, on increasing its investment in Baxter Company Limited (BCL), a joint venture andmanufacturing plant of both companies in the southern region of Saudi Arabia. Baxter and Olayan established their partnership 10 years ago to build a state of the art manufacturing facility to produce medical solutions for peritoneal dialysis and IV solutions that currentlyserves more than 1500 renal dialysis patients in the Saudi region. In the future, the factory will expand its supply beyond Saudi Arabia to the entire Middle East as part of a global supply chain ecosystem.  

The agreement underscores the partner’s commitment to Saudi and the region to further improve clinical outcomes for a wide range of patients suffering from chronic kidney failure (CKD). In addition to expanding capacity in the current manufacturing facility.

“For more than 60 years, Baxter has partnered with the nephrology community to focus on pioneering care in both hemodialysis and peritoneal dialysis”, said Mazen Dalati, General Manager of Baxter Middle East Africa. He continued:” The agreement with Olayan is an important milestone on our way to bring that pioneering spirit to Saudi through new therapies and remote patient management.”

Baxter is bringing into this venture Claria with SHARESOURCE, a new technology that allows remote monitoring of peritoneal therapy patients while in their home. 

SHARESOURCE extends healthcare providers’ reach by allowing visibility to their home patients’ adherence patterns, which may allow for earlier intervention. The telehealth platform was introduced to the Saudi market in 2016. It is the only globally available two-way technology that enables healthcare professionals to remotely monitor and manage therapy from their clinic. Furthermore, Sharesource includes the ability to change a patient’s prescription setting remotely. 

Baxter and Olayan consider themselves partners of the Ministry of Health in their joint effort to facilitate Saudi Arabia’s Vision 2030 by providing lifesaving therapies to patients. Additionally, Baxter and Olayan are committed to localizing the latest technology and know-how for the benefit of the Saudi market.